| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pulmonary Disease, Chronic Obstructive | 27 | 2022 | 207 | 4.550 |
Why?
|
| Pulmonary Emphysema | 18 | 2022 | 71 | 4.210 |
Why?
|
| Lung | 40 | 2022 | 849 | 3.640 |
Why?
|
| Matrix Metalloproteinase 12 | 25 | 2021 | 31 | 2.910 |
Why?
|
| Emphysema | 12 | 2022 | 32 | 2.640 |
Why?
|
| Smoke | 12 | 2020 | 46 | 2.430 |
Why?
|
| Neutrophils | 21 | 2018 | 204 | 2.210 |
Why?
|
| Smoking | 20 | 2017 | 1449 | 1.970 |
Why?
|
| Leukocyte Elastase | 14 | 2021 | 19 | 1.850 |
Why?
|
| Mice | 95 | 2022 | 8472 | 1.800 |
Why?
|
| Genome-Wide Association Study | 6 | 2017 | 240 | 1.690 |
Why?
|
| Animals | 117 | 2022 | 20877 | 1.670 |
Why?
|
| Lung Neoplasms | 14 | 2021 | 1172 | 1.550 |
Why?
|
| Macrophages | 18 | 2021 | 647 | 1.530 |
Why?
|
| Metalloendopeptidases | 17 | 2006 | 67 | 1.380 |
Why?
|
| Tobacco | 12 | 2022 | 161 | 1.360 |
Why?
|
| Lung Diseases | 8 | 2011 | 175 | 1.310 |
Why?
|
| Pulmonary Alveoli | 11 | 2017 | 62 | 1.270 |
Why?
|
| Disease Models, Animal | 27 | 2021 | 2550 | 1.150 |
Why?
|
| Genetic Predisposition to Disease | 9 | 2017 | 785 | 1.080 |
Why?
|
| Macrophages, Alveolar | 13 | 2021 | 34 | 1.080 |
Why?
|
| Stroke | 7 | 2022 | 2161 | 1.010 |
Why?
|
| Mice, Inbred C57BL | 34 | 2017 | 2790 | 0.990 |
Why?
|
| Mice, Knockout | 42 | 2021 | 1692 | 0.980 |
Why?
|
| Humans | 100 | 2022 | 68525 | 0.980 |
Why?
|
| Precision Medicine | 3 | 2017 | 111 | 0.970 |
Why?
|
| Cigarette Smoking | 3 | 2022 | 104 | 0.930 |
Why?
|
| Apoptosis | 9 | 2021 | 1640 | 0.890 |
Why?
|
| Epithelial Cells | 7 | 2021 | 431 | 0.870 |
Why?
|
| Periodicals as Topic | 8 | 2014 | 158 | 0.870 |
Why?
|
| Tobacco Smoke Pollution | 5 | 2021 | 127 | 0.860 |
Why?
|
| Respiration Disorders | 1 | 2022 | 20 | 0.840 |
Why?
|
| ErbB Receptors | 2 | 2017 | 239 | 0.840 |
Why?
|
| Asthma | 7 | 2013 | 345 | 0.820 |
Why?
|
| Receptor-Interacting Protein Serine-Threonine Kinases | 1 | 2021 | 30 | 0.800 |
Why?
|
| Blood Vessels | 3 | 2016 | 102 | 0.790 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2017 | 300 | 0.760 |
Why?
|
| Mice, Inbred Strains | 7 | 2021 | 181 | 0.740 |
Why?
|
| Lung Volume Measurements | 2 | 2018 | 19 | 0.730 |
Why?
|
| PPAR gamma | 4 | 2015 | 95 | 0.720 |
Why?
|
| Schools, Medical | 1 | 2020 | 157 | 0.680 |
Why?
|
| Circle of Willis | 1 | 2018 | 3 | 0.680 |
Why?
|
| Betacoronavirus | 1 | 2020 | 116 | 0.670 |
Why?
|
| Chemotaxis, Leukocyte | 6 | 2009 | 48 | 0.650 |
Why?
|
| Academic Medical Centers | 1 | 2020 | 281 | 0.640 |
Why?
|
| Phagocytosis | 5 | 2019 | 65 | 0.640 |
Why?
|
| Receptor-Like Protein Tyrosine Phosphatases, Class 3 | 1 | 2017 | 1 | 0.620 |
Why?
|
| Inflammation | 17 | 2021 | 1030 | 0.620 |
Why?
|
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2017 | 19 | 0.620 |
Why?
|
| Hypertension, Pulmonary | 2 | 2017 | 232 | 0.610 |
Why?
|
| Cell Proliferation | 7 | 2017 | 1173 | 0.610 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 143 | 0.600 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2017 | 65 | 0.600 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 154 | 0.600 |
Why?
|
| Vascular Calcification | 1 | 2018 | 131 | 0.600 |
Why?
|
| Microscopy | 2 | 2016 | 64 | 0.600 |
Why?
|
| Intracranial Arteriosclerosis | 1 | 2018 | 134 | 0.580 |
Why?
|
| Pandemics | 1 | 2020 | 346 | 0.570 |
Why?
|
| Fibrosis | 5 | 2018 | 371 | 0.570 |
Why?
|
| Gene Expression Profiling | 8 | 2021 | 498 | 0.570 |
Why?
|
| Receptor for Advanced Glycation End Products | 2 | 2015 | 19 | 0.550 |
Why?
|
| Matrix Metalloproteinase 8 | 5 | 2009 | 22 | 0.540 |
Why?
|
| Patient-Centered Care | 1 | 2016 | 106 | 0.530 |
Why?
|
| Psychotherapy, Group | 1 | 2015 | 55 | 0.520 |
Why?
|
| Adipose Tissue, White | 1 | 2014 | 7 | 0.520 |
Why?
|
| Mindfulness | 1 | 2015 | 41 | 0.520 |
Why?
|
| Respiratory Hypersensitivity | 3 | 2010 | 12 | 0.510 |
Why?
|
| Chemokines, CXC | 2 | 2006 | 16 | 0.510 |
Why?
|
| Cost-Benefit Analysis | 1 | 2017 | 503 | 0.510 |
Why?
|
| Female | 48 | 2022 | 38015 | 0.510 |
Why?
|
| Elastin | 6 | 2007 | 116 | 0.510 |
Why?
|
| Biomedical Research | 3 | 2009 | 310 | 0.500 |
Why?
|
| Matrix Metalloproteinase 9 | 11 | 2009 | 160 | 0.500 |
Why?
|
| Image Processing, Computer-Assisted | 4 | 2016 | 689 | 0.490 |
Why?
|
| Carrier Proteins | 1 | 2017 | 597 | 0.490 |
Why?
|
| Pulmonary Ventilation | 1 | 2014 | 28 | 0.480 |
Why?
|
| Interferon-alpha | 1 | 2014 | 46 | 0.480 |
Why?
|
| Electronic Nicotine Delivery Systems | 1 | 2016 | 180 | 0.480 |
Why?
|
| Cells, Cultured | 15 | 2021 | 2673 | 0.480 |
Why?
|
| Immunity | 1 | 2014 | 67 | 0.480 |
Why?
|
| Thiazolidinediones | 1 | 2014 | 76 | 0.470 |
Why?
|
| Leptin | 1 | 2014 | 80 | 0.470 |
Why?
|
| Genomics | 4 | 2019 | 167 | 0.470 |
Why?
|
| Respiratory Mucosa | 4 | 2006 | 52 | 0.460 |
Why?
|
| Pharynx | 1 | 2014 | 89 | 0.460 |
Why?
|
| Seizures | 1 | 2015 | 279 | 0.460 |
Why?
|
| Tissue Inhibitor of Metalloproteinases | 2 | 2004 | 85 | 0.450 |
Why?
|
| Mass Screening | 2 | 2017 | 837 | 0.450 |
Why?
|
| Telomere | 2 | 2021 | 59 | 0.450 |
Why?
|
| Cell Nucleus | 1 | 2014 | 305 | 0.450 |
Why?
|
| Skin Aging | 1 | 2012 | 8 | 0.440 |
Why?
|
| Mice, Transgenic | 13 | 2019 | 1032 | 0.440 |
Why?
|
| Social Support | 1 | 2015 | 423 | 0.430 |
Why?
|
| Adult Stem Cells | 1 | 2012 | 13 | 0.430 |
Why?
|
| Vasospasm, Intracranial | 2 | 2022 | 16 | 0.430 |
Why?
|
| Leukocyte Common Antigens | 1 | 2012 | 41 | 0.430 |
Why?
|
| CD11b Antigen | 1 | 2012 | 47 | 0.430 |
Why?
|
| Cell Death | 2 | 2017 | 329 | 0.430 |
Why?
|
| Alveolar Epithelial Cells | 1 | 2012 | 28 | 0.420 |
Why?
|
| Pneumonia | 3 | 2014 | 110 | 0.420 |
Why?
|
| Chemokines | 6 | 2015 | 119 | 0.420 |
Why?
|
| Early Detection of Cancer | 1 | 2017 | 439 | 0.410 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2014 | 142 | 0.410 |
Why?
|
| Subarachnoid Hemorrhage | 2 | 2022 | 61 | 0.410 |
Why?
|
| Sleep | 1 | 2014 | 263 | 0.410 |
Why?
|
| Obesity, Morbid | 1 | 2014 | 172 | 0.410 |
Why?
|
| Dendritic Cells | 3 | 2008 | 201 | 0.400 |
Why?
|
| Male | 34 | 2021 | 37281 | 0.400 |
Why?
|
| Quantitative Trait Loci | 2 | 2010 | 35 | 0.390 |
Why?
|
| Telomerase | 1 | 2011 | 85 | 0.390 |
Why?
|
| Neutrophil Infiltration | 5 | 2006 | 35 | 0.380 |
Why?
|
| LIM Domain Proteins | 2 | 2021 | 15 | 0.380 |
Why?
|
| Signal Transduction | 9 | 2015 | 2688 | 0.380 |
Why?
|
| Adenocarcinoma | 2 | 2012 | 475 | 0.370 |
Why?
|
| Pancreatic Elastase | 7 | 2009 | 33 | 0.370 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2010 | 18 | 0.370 |
Why?
|
| Monocytes | 7 | 2021 | 210 | 0.360 |
Why?
|
| Matrix Metalloproteinase 7 | 4 | 2003 | 15 | 0.360 |
Why?
|
| Bacterial Physiological Phenomena | 1 | 2009 | 7 | 0.360 |
Why?
|
| Wound Healing | 3 | 2007 | 260 | 0.350 |
Why?
|
| Sepsis | 3 | 2020 | 233 | 0.350 |
Why?
|
| Cell Membrane Permeability | 1 | 2009 | 59 | 0.350 |
Why?
|
| STAT3 Transcription Factor | 4 | 2021 | 86 | 0.350 |
Why?
|
| Pulmonary Fibrosis | 4 | 2010 | 157 | 0.350 |
Why?
|
| Disease Progression | 10 | 2017 | 1037 | 0.340 |
Why?
|
| Polymorphism, Single Nucleotide | 7 | 2020 | 627 | 0.340 |
Why?
|
| Actins | 1 | 2010 | 249 | 0.340 |
Why?
|
| Acute Lung Injury | 1 | 2009 | 35 | 0.330 |
Why?
|
| Ventilators, Mechanical | 1 | 2008 | 13 | 0.320 |
Why?
|
| Stem Cells | 3 | 2011 | 248 | 0.320 |
Why?
|
| Cell Line | 6 | 2021 | 1752 | 0.320 |
Why?
|
| Cell Movement | 8 | 2021 | 630 | 0.320 |
Why?
|
| United States | 9 | 2022 | 7335 | 0.320 |
Why?
|
| Publishing | 5 | 2014 | 89 | 0.320 |
Why?
|
| Surveys and Questionnaires | 1 | 2016 | 2798 | 0.320 |
Why?
|
| Bacterial Infections | 1 | 2009 | 163 | 0.310 |
Why?
|
| Lymph Nodes | 2 | 2008 | 258 | 0.310 |
Why?
|
| Aged, 80 and over | 9 | 2022 | 4843 | 0.310 |
Why?
|
| Extravascular Lung Water | 1 | 2007 | 5 | 0.310 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 2 | 2021 | 66 | 0.310 |
Why?
|
| Aged | 16 | 2022 | 14842 | 0.300 |
Why?
|
| Extracellular Matrix | 5 | 2011 | 493 | 0.300 |
Why?
|
| Pulmonary Edema | 1 | 2007 | 37 | 0.300 |
Why?
|
| Eosinophils | 2 | 2006 | 60 | 0.300 |
Why?
|
| Bone Marrow Cells | 3 | 2021 | 217 | 0.290 |
Why?
|
| Respiratory System | 2 | 2018 | 28 | 0.290 |
Why?
|
| T-Lymphocytes | 4 | 2011 | 595 | 0.290 |
Why?
|
| Cell Line, Tumor | 6 | 2020 | 1849 | 0.290 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2015 | 265 | 0.290 |
Why?
|
| Adenosine | 1 | 2007 | 165 | 0.290 |
Why?
|
| Airway Resistance | 3 | 2011 | 7 | 0.290 |
Why?
|
| Cystic Fibrosis | 1 | 2010 | 283 | 0.290 |
Why?
|
| Carcinoma, Lewis Lung | 1 | 2006 | 20 | 0.280 |
Why?
|
| Middle Aged | 16 | 2022 | 21119 | 0.280 |
Why?
|
| Brain Ischemia | 2 | 2022 | 665 | 0.280 |
Why?
|
| Cyclic AMP | 1 | 2006 | 223 | 0.280 |
Why?
|
| Cell Membrane | 3 | 2008 | 523 | 0.280 |
Why?
|
| Adult | 13 | 2022 | 21375 | 0.270 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 5 | 2013 | 320 | 0.260 |
Why?
|
| Acetyltransferases | 1 | 2005 | 49 | 0.260 |
Why?
|
| Breast Neoplasms | 3 | 2022 | 1533 | 0.260 |
Why?
|
| Gene Expression | 7 | 2015 | 770 | 0.260 |
Why?
|
| Membrane Proteins | 1 | 2009 | 617 | 0.250 |
Why?
|
| Bronchoalveolar Lavage Fluid | 11 | 2010 | 117 | 0.250 |
Why?
|
| Orthomyxoviridae Infections | 1 | 2004 | 4 | 0.250 |
Why?
|
| Proteoglycans | 2 | 2013 | 103 | 0.250 |
Why?
|
| Activin Receptors, Type I | 2 | 2019 | 14 | 0.240 |
Why?
|
| Histone Deacetylases | 1 | 2005 | 99 | 0.240 |
Why?
|
| B7-H1 Antigen | 2 | 2021 | 30 | 0.240 |
Why?
|
| Lung Transplantation | 2 | 2021 | 88 | 0.240 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2004 | 41 | 0.240 |
Why?
|
| Molecular Biology | 1 | 2003 | 31 | 0.240 |
Why?
|
| Mutation | 6 | 2020 | 1213 | 0.230 |
Why?
|
| DNA | 3 | 2019 | 597 | 0.230 |
Why?
|
| Peptide Fragments | 1 | 2006 | 483 | 0.230 |
Why?
|
| Collagen | 7 | 2011 | 636 | 0.230 |
Why?
|
| Pulmonary Surfactant-Associated Protein D | 3 | 2010 | 15 | 0.230 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2005 | 167 | 0.230 |
Why?
|
| Reactive Oxygen Species | 4 | 2021 | 499 | 0.230 |
Why?
|
| Chemotactic Factors | 1 | 2003 | 14 | 0.230 |
Why?
|
| Immunohistochemistry | 7 | 2015 | 1174 | 0.230 |
Why?
|
| Inflammation Mediators | 4 | 2005 | 244 | 0.230 |
Why?
|
| Sequence Analysis, RNA | 2 | 2021 | 34 | 0.220 |
Why?
|
| Protein-Lysine 6-Oxidase | 1 | 2002 | 14 | 0.220 |
Why?
|
| Diaphragm | 1 | 2002 | 22 | 0.220 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2003 | 146 | 0.220 |
Why?
|
| Integrins | 3 | 2012 | 115 | 0.220 |
Why?
|
| Gene Expression Regulation, Enzymologic | 3 | 2013 | 282 | 0.220 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2020 | 66 | 0.220 |
Why?
|
| Cross-Sectional Studies | 5 | 2022 | 2264 | 0.220 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2021 | 214 | 0.220 |
Why?
|
| RNA | 3 | 2021 | 171 | 0.220 |
Why?
|
| Ischemic Attack, Transient | 2 | 2019 | 167 | 0.220 |
Why?
|
| Intracranial Arteriovenous Malformations | 1 | 2022 | 15 | 0.220 |
Why?
|
| Gene Expression Regulation | 5 | 2020 | 1293 | 0.220 |
Why?
|
| Hyponatremia | 1 | 2022 | 20 | 0.220 |
Why?
|
| Intracranial Hemorrhage, Traumatic | 1 | 2022 | 1 | 0.220 |
Why?
|
| Peptide Hydrolases | 3 | 2018 | 82 | 0.210 |
Why?
|
| Proteinase Inhibitory Proteins, Secretory | 1 | 2021 | 3 | 0.210 |
Why?
|
| Subclavian Artery | 1 | 2022 | 30 | 0.210 |
Why?
|
| Health Care Costs | 2 | 2017 | 346 | 0.210 |
Why?
|
| Atherosclerosis | 2 | 2014 | 204 | 0.210 |
Why?
|
| Hematoma | 1 | 2022 | 47 | 0.210 |
Why?
|
| Immunotherapy | 2 | 2021 | 212 | 0.210 |
Why?
|
| Interleukin-6 | 2 | 2015 | 330 | 0.200 |
Why?
|
| Models, Biological | 6 | 2009 | 981 | 0.200 |
Why?
|
| Membrane Glycoproteins | 2 | 2005 | 370 | 0.200 |
Why?
|
| Electronic Health Records | 2 | 2017 | 374 | 0.200 |
Why?
|
| Dichloroacetic Acid | 1 | 2020 | 5 | 0.200 |
Why?
|
| Flow Cytometry | 3 | 2017 | 489 | 0.200 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 5 | 1 | 2021 | 18 | 0.200 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2021 | 53 | 0.200 |
Why?
|
| Receptors, Chemokine | 2 | 2011 | 26 | 0.190 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2021 | 125 | 0.190 |
Why?
|
| Base Sequence | 5 | 2013 | 1015 | 0.190 |
Why?
|
| Unnecessary Procedures | 1 | 2021 | 49 | 0.190 |
Why?
|
| Mice, Inbred AKR | 2 | 2017 | 8 | 0.190 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2021 | 110 | 0.190 |
Why?
|
| Allergens | 3 | 2005 | 54 | 0.190 |
Why?
|
| National Institutes of Health (U.S.) | 3 | 2005 | 109 | 0.190 |
Why?
|
| Follistatin-Related Proteins | 1 | 2020 | 1 | 0.190 |
Why?
|
| Immunity, Innate | 3 | 2018 | 156 | 0.190 |
Why?
|
| Bleomycin | 3 | 2007 | 67 | 0.190 |
Why?
|
| Disease Susceptibility | 3 | 2017 | 179 | 0.190 |
Why?
|
| Severity of Illness Index | 4 | 2021 | 1851 | 0.190 |
Why?
|
| Cerebral Hemorrhage | 1 | 2022 | 198 | 0.190 |
Why?
|
| Longevity | 1 | 2020 | 59 | 0.190 |
Why?
|
| Public Policy | 3 | 2005 | 71 | 0.190 |
Why?
|
| Oncolytic Virotherapy | 1 | 2020 | 15 | 0.190 |
Why?
|
| Personal Protective Equipment | 1 | 2020 | 27 | 0.180 |
Why?
|
| Colitis | 1 | 2021 | 156 | 0.180 |
Why?
|
| Epigenetic Repression | 1 | 2019 | 1 | 0.180 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 60 | 0.180 |
Why?
|
| Diet, High-Fat | 2 | 2017 | 81 | 0.180 |
Why?
|
| Aorta, Thoracic | 1 | 2022 | 211 | 0.180 |
Why?
|
| Drosophila melanogaster | 1 | 2020 | 80 | 0.180 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2022 | 333 | 0.180 |
Why?
|
| Up-Regulation | 4 | 2017 | 682 | 0.180 |
Why?
|
| Neoplasms, Experimental | 1 | 2020 | 118 | 0.180 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2019 | 19 | 0.180 |
Why?
|
| Phagosomes | 1 | 2019 | 19 | 0.180 |
Why?
|
| Emergency Medical Services | 1 | 2022 | 225 | 0.180 |
Why?
|
| Pneumonia, Bacterial | 1 | 2019 | 19 | 0.180 |
Why?
|
| Transcriptome | 1 | 2021 | 164 | 0.180 |
Why?
|
| Receptors, Cell Surface | 3 | 2006 | 248 | 0.180 |
Why?
|
| Pemphigoid, Bullous | 2 | 2011 | 13 | 0.170 |
Why?
|
| Microfilament Proteins | 1 | 2019 | 102 | 0.170 |
Why?
|
| RNA-Binding Proteins | 1 | 2021 | 215 | 0.170 |
Why?
|
| Blotting, Western | 7 | 2017 | 954 | 0.170 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2019 | 756 | 0.170 |
Why?
|
| Reproducibility of Results | 5 | 2017 | 2077 | 0.170 |
Why?
|
| Cytokines | 11 | 2014 | 866 | 0.170 |
Why?
|
| DNA Primers | 3 | 2009 | 302 | 0.170 |
Why?
|
| Autopsy | 1 | 2018 | 56 | 0.170 |
Why?
|
| Wakefulness-Promoting Agents | 1 | 2018 | 6 | 0.170 |
Why?
|
| Tranylcypromine | 1 | 2018 | 8 | 0.170 |
Why?
|
| Monoamine Oxidase Inhibitors | 1 | 2018 | 30 | 0.170 |
Why?
|
| Editorial Policies | 2 | 2008 | 32 | 0.170 |
Why?
|
| Transforming Growth Factor beta | 4 | 2011 | 384 | 0.160 |
Why?
|
| Receptors, Immunologic | 2 | 2010 | 72 | 0.160 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2015 | 710 | 0.160 |
Why?
|
| Headache | 1 | 2018 | 68 | 0.160 |
Why?
|
| Cathepsins | 3 | 2007 | 37 | 0.160 |
Why?
|
| Hematopoietic Stem Cells | 3 | 2012 | 268 | 0.160 |
Why?
|
| alpha 1-Antitrypsin | 3 | 2011 | 61 | 0.160 |
Why?
|
| Amines | 1 | 2018 | 98 | 0.160 |
Why?
|
| RNA, Messenger | 9 | 2014 | 1663 | 0.150 |
Why?
|
| Endovascular Procedures | 1 | 2022 | 366 | 0.150 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2018 | 125 | 0.150 |
Why?
|
| Health Records, Personal | 1 | 2017 | 8 | 0.150 |
Why?
|
| Genome, Human | 1 | 2017 | 62 | 0.150 |
Why?
|
| Cell Differentiation | 5 | 2011 | 1034 | 0.150 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2010 | 216 | 0.150 |
Why?
|
| Basement Membrane | 3 | 2021 | 48 | 0.150 |
Why?
|
| Cholesterol | 1 | 2018 | 331 | 0.150 |
Why?
|
| Pharmacogenetics | 1 | 2017 | 47 | 0.150 |
Why?
|
| Health Care Reform | 1 | 2017 | 62 | 0.150 |
Why?
|
| Ambulatory Care | 1 | 2019 | 339 | 0.150 |
Why?
|
| Bronchi | 3 | 2011 | 59 | 0.150 |
Why?
|
| Bronchiolitis Obliterans | 2 | 2009 | 15 | 0.150 |
Why?
|
| Gene Deletion | 3 | 2015 | 235 | 0.150 |
Why?
|
| Automation | 1 | 2016 | 45 | 0.140 |
Why?
|
| Th2 Cells | 3 | 2005 | 48 | 0.140 |
Why?
|
| Vascular Remodeling | 1 | 2016 | 34 | 0.140 |
Why?
|
| Gene Regulatory Networks | 1 | 2017 | 94 | 0.140 |
Why?
|
| Endothelium, Vascular | 4 | 2008 | 371 | 0.140 |
Why?
|
| Mitochondria | 2 | 2019 | 643 | 0.140 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2011 | 626 | 0.140 |
Why?
|
| Species Specificity | 2 | 2008 | 302 | 0.140 |
Why?
|
| Osteoclasts | 2 | 2009 | 132 | 0.140 |
Why?
|
| Anti-Infective Agents | 1 | 2017 | 166 | 0.140 |
Why?
|
| Biomarkers | 6 | 2014 | 1593 | 0.140 |
Why?
|
| Retrospective Studies | 5 | 2022 | 7264 | 0.140 |
Why?
|
| Sputum | 2 | 2018 | 51 | 0.130 |
Why?
|
| Amyloid beta-Protein Precursor | 2 | 2006 | 115 | 0.130 |
Why?
|
| Catalysis | 3 | 2005 | 123 | 0.130 |
Why?
|
| Hemodynamics | 2 | 2017 | 705 | 0.130 |
Why?
|
| alpha 1-Antitrypsin Deficiency | 1 | 2015 | 37 | 0.130 |
Why?
|
| 3T3-L1 Cells | 1 | 2014 | 30 | 0.130 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2014 | 219 | 0.130 |
Why?
|
| Endostatins | 1 | 2014 | 11 | 0.130 |
Why?
|
| Bone Marrow Transplantation | 3 | 2011 | 149 | 0.130 |
Why?
|
| Metabolic Syndrome | 1 | 2017 | 191 | 0.130 |
Why?
|
| Cell Adhesion | 5 | 2011 | 324 | 0.130 |
Why?
|
| DNA Damage | 2 | 2013 | 190 | 0.130 |
Why?
|
| Phosphorylation | 3 | 2020 | 1199 | 0.130 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2022 | 194 | 0.120 |
Why?
|
| Mice, Inbred BALB C | 4 | 2009 | 532 | 0.120 |
Why?
|
| Time Factors | 6 | 2012 | 4655 | 0.120 |
Why?
|
| Stroke Volume | 1 | 2017 | 586 | 0.120 |
Why?
|
| Th1 Cells | 2 | 2005 | 101 | 0.120 |
Why?
|
| Phenotype | 5 | 2013 | 946 | 0.120 |
Why?
|
| Adiposity | 1 | 2014 | 88 | 0.120 |
Why?
|
| Respiratory Tract Diseases | 1 | 2014 | 43 | 0.120 |
Why?
|
| Neoplasms | 2 | 2021 | 1660 | 0.120 |
Why?
|
| Staphylococcus aureus | 2 | 2019 | 175 | 0.120 |
Why?
|
| Mucous Membrane | 2 | 2011 | 66 | 0.120 |
Why?
|
| Models, Molecular | 2 | 2021 | 546 | 0.120 |
Why?
|
| Computer Simulation | 1 | 2017 | 705 | 0.120 |
Why?
|
| Intervertebral Disc Degeneration | 1 | 2013 | 20 | 0.120 |
Why?
|
| Genetic Therapy | 1 | 2015 | 291 | 0.120 |
Why?
|
| Integrin beta Chains | 2 | 2011 | 7 | 0.120 |
Why?
|
| Aortic Aneurysm, Abdominal | 2 | 2005 | 139 | 0.120 |
Why?
|
| Enzyme Activation | 3 | 2010 | 791 | 0.120 |
Why?
|
| Autophagy | 1 | 2015 | 207 | 0.120 |
Why?
|
| Serpins | 2 | 2006 | 205 | 0.120 |
Why?
|
| Kv Channel-Interacting Proteins | 1 | 2013 | 3 | 0.110 |
Why?
|
| Healthcare Disparities | 1 | 2017 | 378 | 0.110 |
Why?
|
| Homeostasis | 3 | 2015 | 291 | 0.110 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2013 | 74 | 0.110 |
Why?
|
| Lymphocyte Activation | 2 | 2020 | 397 | 0.110 |
Why?
|
| Cancer Care Facilities | 1 | 2012 | 32 | 0.110 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2013 | 124 | 0.110 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2012 | 624 | 0.110 |
Why?
|
| Mastectomy | 1 | 2012 | 56 | 0.110 |
Why?
|
| Delivery of Health Care | 1 | 2017 | 445 | 0.110 |
Why?
|
| In Situ Hybridization | 4 | 2007 | 201 | 0.110 |
Why?
|
| Cosmetic Techniques | 1 | 2012 | 6 | 0.110 |
Why?
|
| Protein Folding | 1 | 2012 | 82 | 0.110 |
Why?
|
| Protein Disulfide-Isomerases | 1 | 2012 | 27 | 0.110 |
Why?
|
| Body Weight | 1 | 2014 | 554 | 0.110 |
Why?
|
| Urethane | 3 | 2020 | 4 | 0.110 |
Why?
|
| Heart Ventricles | 1 | 2017 | 738 | 0.110 |
Why?
|
| Cost Control | 1 | 2012 | 34 | 0.110 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 3 | 2019 | 78 | 0.110 |
Why?
|
| Haplotypes | 2 | 2010 | 174 | 0.110 |
Why?
|
| Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2012 | 1 | 0.110 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2012 | 99 | 0.110 |
Why?
|
| Anti-Bacterial Agents | 2 | 2009 | 1026 | 0.100 |
Why?
|
| Hemidesmosomes | 1 | 2011 | 1 | 0.100 |
Why?
|
| Non-Fibrillar Collagens | 1 | 2011 | 9 | 0.100 |
Why?
|
| Endoplasmic Reticulum | 1 | 2012 | 148 | 0.100 |
Why?
|
| Intracranial Hemorrhages | 2 | 2022 | 80 | 0.100 |
Why?
|
| Receptors, Interleukin-17 | 1 | 2011 | 5 | 0.100 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2016 | 2083 | 0.100 |
Why?
|
| Molecular Sequence Data | 3 | 2009 | 1446 | 0.100 |
Why?
|
| Polymorphism, Genetic | 2 | 2010 | 301 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2015 | 929 | 0.100 |
Why?
|
| Proteomics | 2 | 2018 | 246 | 0.100 |
Why?
|
| Mononuclear Phagocyte System | 1 | 2011 | 8 | 0.100 |
Why?
|
| Hydroxyproline | 3 | 2010 | 33 | 0.100 |
Why?
|
| Autoantigens | 1 | 2011 | 91 | 0.100 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2009 | 282 | 0.100 |
Why?
|
| Protein Structure, Tertiary | 2 | 2009 | 322 | 0.100 |
Why?
|
| Chemokine CCL2 | 1 | 2011 | 101 | 0.100 |
Why?
|
| Neovascularization, Pathologic | 3 | 2009 | 183 | 0.100 |
Why?
|
| Plethysmography | 1 | 2010 | 17 | 0.100 |
Why?
|
| Treatment Outcome | 6 | 2022 | 7028 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-vav | 1 | 2010 | 4 | 0.100 |
Why?
|
| Administration, Inhalation | 3 | 2005 | 187 | 0.090 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2012 | 284 | 0.090 |
Why?
|
| Cell Count | 2 | 2008 | 248 | 0.090 |
Why?
|
| Risk Factors | 6 | 2022 | 5719 | 0.090 |
Why?
|
| Silicosis | 1 | 2010 | 1 | 0.090 |
Why?
|
| rac1 GTP-Binding Protein | 1 | 2010 | 23 | 0.090 |
Why?
|
| Endothelial Cells | 2 | 2020 | 384 | 0.090 |
Why?
|
| Chromosomes | 1 | 2010 | 17 | 0.090 |
Why?
|
| Dyspnea | 1 | 2010 | 87 | 0.090 |
Why?
|
| Metatarsal Bones | 1 | 2009 | 3 | 0.090 |
Why?
|
| Iron Regulatory Protein 2 | 1 | 2009 | 1 | 0.090 |
Why?
|
| Transcription Factor RelA | 2 | 2020 | 47 | 0.090 |
Why?
|
| Aorta | 3 | 2014 | 316 | 0.090 |
Why?
|
| Hydrolysis | 1 | 2010 | 144 | 0.090 |
Why?
|
| Macrophages, Peritoneal | 2 | 2011 | 67 | 0.090 |
Why?
|
| Forced Expiratory Volume | 1 | 2009 | 87 | 0.090 |
Why?
|
| Chromosome Mapping | 1 | 2010 | 188 | 0.090 |
Why?
|
| Matrix Metalloproteinases | 3 | 2006 | 223 | 0.090 |
Why?
|
| Claudins | 1 | 2009 | 6 | 0.090 |
Why?
|
| Cause of Death | 1 | 2010 | 241 | 0.090 |
Why?
|
| Klebsiella pneumoniae | 1 | 2009 | 18 | 0.090 |
Why?
|
| Amino Acid Sequence | 2 | 2009 | 1082 | 0.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2012 | 467 | 0.090 |
Why?
|
| Collagen Type IV | 3 | 2005 | 28 | 0.090 |
Why?
|
| Diagnosis, Differential | 2 | 2012 | 1139 | 0.090 |
Why?
|
| Gene Knockdown Techniques | 2 | 2020 | 196 | 0.090 |
Why?
|
| Microcystins | 1 | 2009 | 7 | 0.090 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2020 | 86 | 0.090 |
Why?
|
| Total Lung Capacity | 1 | 2009 | 14 | 0.090 |
Why?
|
| Surface Tension | 1 | 2009 | 13 | 0.090 |
Why?
|
| Glycation End Products, Advanced | 1 | 2010 | 125 | 0.090 |
Why?
|
| Thrombectomy | 2 | 2022 | 238 | 0.090 |
Why?
|
| Mice, Mutant Strains | 2 | 2007 | 166 | 0.090 |
Why?
|
| Clarithromycin | 1 | 2008 | 11 | 0.090 |
Why?
|
| Fibroblasts | 4 | 2011 | 902 | 0.080 |
Why?
|
| Elasticity | 1 | 2009 | 103 | 0.080 |
Why?
|
| Pulmonary Surfactants | 1 | 2009 | 41 | 0.080 |
Why?
|
| Hypertension | 1 | 2018 | 1531 | 0.080 |
Why?
|
| Photography | 1 | 2008 | 37 | 0.080 |
Why?
|
| Flavonoids | 1 | 2009 | 109 | 0.080 |
Why?
|
| Animals, Genetically Modified | 1 | 2008 | 63 | 0.080 |
Why?
|
| Peer Review, Research | 1 | 2008 | 21 | 0.080 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2022 | 444 | 0.080 |
Why?
|
| Neovascularization, Physiologic | 1 | 2009 | 164 | 0.080 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2008 | 97 | 0.080 |
Why?
|
| NADPH Oxidases | 2 | 2006 | 80 | 0.080 |
Why?
|
| Caveolin 1 | 1 | 2008 | 59 | 0.080 |
Why?
|
| Bronchoalveolar Lavage | 3 | 2017 | 15 | 0.080 |
Why?
|
| Proteins | 3 | 2007 | 473 | 0.080 |
Why?
|
| Thorax | 1 | 2008 | 49 | 0.080 |
Why?
|
| Tidal Volume | 1 | 2008 | 17 | 0.080 |
Why?
|
| Cell Lineage | 2 | 2011 | 146 | 0.080 |
Why?
|
| Cell Division | 1 | 2009 | 541 | 0.080 |
Why?
|
| Gene Targeting | 2 | 2005 | 58 | 0.080 |
Why?
|
| Leukocytes | 2 | 2005 | 99 | 0.080 |
Why?
|
| Congresses as Topic | 1 | 2008 | 85 | 0.080 |
Why?
|
| Respiration | 1 | 2008 | 91 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2009 | 536 | 0.080 |
Why?
|
| Heart Failure | 1 | 2017 | 1179 | 0.080 |
Why?
|
| Antigen Presentation | 1 | 2008 | 76 | 0.080 |
Why?
|
| Collagenases | 2 | 2004 | 34 | 0.080 |
Why?
|
| Haemophilus Infections | 1 | 2007 | 15 | 0.080 |
Why?
|
| Pulmonary Veins | 1 | 2008 | 56 | 0.080 |
Why?
|
| Incidence | 2 | 2022 | 1582 | 0.080 |
Why?
|
| Scavenger Receptors, Class A | 1 | 2007 | 3 | 0.080 |
Why?
|
| Organ Size | 1 | 2008 | 242 | 0.080 |
Why?
|
| In Vitro Techniques | 3 | 2020 | 765 | 0.080 |
Why?
|
| Desmosine | 2 | 2007 | 4 | 0.080 |
Why?
|
| Adenosine A2 Receptor Antagonists | 1 | 2007 | 4 | 0.080 |
Why?
|
| X-Ray Microtomography | 2 | 2020 | 50 | 0.080 |
Why?
|
| Hyperoxia | 1 | 2007 | 27 | 0.080 |
Why?
|
| Ion Transport | 1 | 2007 | 26 | 0.080 |
Why?
|
| Bronchopulmonary Dysplasia | 1 | 2007 | 34 | 0.080 |
Why?
|
| fas Receptor | 1 | 2007 | 54 | 0.080 |
Why?
|
| Epithelial Sodium Channels | 1 | 2007 | 25 | 0.070 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2008 | 231 | 0.070 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2007 | 51 | 0.070 |
Why?
|
| Receptors, Fc | 1 | 2006 | 19 | 0.070 |
Why?
|
| Shwartzman Phenomenon | 1 | 2006 | 1 | 0.070 |
Why?
|
| Cell Cycle Proteins | 1 | 2008 | 230 | 0.070 |
Why?
|
| Macrophage-1 Antigen | 1 | 2006 | 10 | 0.070 |
Why?
|
| Alleles | 2 | 2009 | 386 | 0.070 |
Why?
|
| Angiostatins | 1 | 2006 | 3 | 0.070 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2022 | 411 | 0.070 |
Why?
|
| Sodium | 1 | 2007 | 161 | 0.070 |
Why?
|
| Diagnostic Imaging | 1 | 2008 | 201 | 0.070 |
Why?
|
| Mice, Inbred C3H | 1 | 2006 | 134 | 0.070 |
Why?
|
| Cell Growth Processes | 1 | 2006 | 40 | 0.070 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2008 | 237 | 0.070 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2006 | 127 | 0.070 |
Why?
|
| Paracrine Communication | 1 | 2006 | 31 | 0.070 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2009 | 331 | 0.070 |
Why?
|
| Environmental Exposure | 1 | 2008 | 269 | 0.070 |
Why?
|
| Homozygote | 2 | 2005 | 119 | 0.070 |
Why?
|
| Pulmonary Surfactant-Associated Protein A | 1 | 2006 | 16 | 0.070 |
Why?
|
| Blotting, Northern | 2 | 2004 | 189 | 0.070 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 2006 | 48 | 0.070 |
Why?
|
| src-Family Kinases | 1 | 2006 | 91 | 0.070 |
Why?
|
| Recombinant Proteins | 2 | 2005 | 742 | 0.070 |
Why?
|
| Fucose | 1 | 2005 | 25 | 0.070 |
Why?
|
| Transcription Factors | 1 | 2010 | 753 | 0.070 |
Why?
|
| Genetic Linkage | 1 | 2005 | 90 | 0.070 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2006 | 195 | 0.070 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2005 | 56 | 0.070 |
Why?
|
| Cerebral Infarction | 2 | 2022 | 103 | 0.070 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2007 | 226 | 0.070 |
Why?
|
| Histone Acetyltransferases | 1 | 2005 | 13 | 0.070 |
Why?
|
| Melanoma, Experimental | 1 | 2006 | 95 | 0.070 |
Why?
|
| Lipopolysaccharides | 2 | 2005 | 455 | 0.070 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2005 | 137 | 0.070 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2005 | 23 | 0.070 |
Why?
|
| Serine Endopeptidases | 1 | 2005 | 50 | 0.070 |
Why?
|
| Regeneration | 1 | 2006 | 105 | 0.070 |
Why?
|
| Oxidants | 1 | 2005 | 48 | 0.070 |
Why?
|
| Cockroaches | 1 | 2004 | 4 | 0.070 |
Why?
|
| Acetylation | 1 | 2005 | 94 | 0.070 |
Why?
|
| Bronchial Hyperreactivity | 1 | 2004 | 10 | 0.060 |
Why?
|
| Kinetics | 2 | 2005 | 1047 | 0.060 |
Why?
|
| Thrombosis | 1 | 2006 | 218 | 0.060 |
Why?
|
| Lovastatin | 1 | 2005 | 78 | 0.060 |
Why?
|
| Catalytic Domain | 1 | 2005 | 99 | 0.060 |
Why?
|
| Neutrophil Activation | 1 | 2004 | 3 | 0.060 |
Why?
|
| Cohort Studies | 4 | 2013 | 2356 | 0.060 |
Why?
|
| DNA-Binding Proteins | 1 | 2008 | 700 | 0.060 |
Why?
|
| Tissue Distribution | 1 | 2005 | 282 | 0.060 |
Why?
|
| Indoles | 1 | 2005 | 146 | 0.060 |
Why?
|
| Tretinoin | 1 | 2005 | 92 | 0.060 |
Why?
|
| Blood-Brain Barrier | 1 | 2005 | 99 | 0.060 |
Why?
|
| Zymosan | 1 | 2004 | 12 | 0.060 |
Why?
|
| Prospective Studies | 3 | 2022 | 3702 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2012 | 2323 | 0.060 |
Why?
|
| Models, Immunological | 1 | 2004 | 25 | 0.060 |
Why?
|
| Bone Resorption | 1 | 2004 | 64 | 0.060 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2005 | 186 | 0.060 |
Why?
|
| Interleukin-13 | 1 | 2003 | 16 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2008 | 1745 | 0.060 |
Why?
|
| Biomarkers, Tumor | 2 | 2009 | 508 | 0.060 |
Why?
|
| N-Formylmethionine Leucyl-Phenylalanine | 1 | 2003 | 7 | 0.060 |
Why?
|
| Mice, 129 Strain | 2 | 2015 | 44 | 0.060 |
Why?
|
| Promoter Regions, Genetic | 2 | 2019 | 614 | 0.060 |
Why?
|
| Gelatin | 1 | 2003 | 14 | 0.060 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-2 | 1 | 2003 | 20 | 0.060 |
Why?
|
| Syndecans | 1 | 2003 | 1 | 0.060 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2005 | 212 | 0.060 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2003 | 73 | 0.060 |
Why?
|
| Corneal Neovascularization | 1 | 2003 | 6 | 0.060 |
Why?
|
| Photorefractive Keratectomy | 1 | 2003 | 12 | 0.060 |
Why?
|
| Skin Neoplasms | 2 | 2007 | 375 | 0.060 |
Why?
|
| Chemokine CXCL1 | 1 | 2003 | 21 | 0.060 |
Why?
|
| Eosinophilia | 1 | 2003 | 47 | 0.060 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2003 | 59 | 0.060 |
Why?
|
| Blotting, Southern | 1 | 2002 | 67 | 0.060 |
Why?
|
| Drug Design | 1 | 2003 | 107 | 0.060 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2005 | 328 | 0.060 |
Why?
|
| Arteriosclerosis | 1 | 2003 | 137 | 0.060 |
Why?
|
| Genotype | 3 | 2013 | 785 | 0.060 |
Why?
|
| Interferon-gamma | 1 | 2004 | 241 | 0.060 |
Why?
|
| Vulvar Neoplasms | 1 | 2002 | 21 | 0.060 |
Why?
|
| Polymers | 1 | 2005 | 244 | 0.060 |
Why?
|
| Antioxidants | 1 | 2005 | 304 | 0.060 |
Why?
|
| Cornea | 1 | 2003 | 76 | 0.060 |
Why?
|
| Cell Adhesion Molecules | 3 | 2014 | 199 | 0.060 |
Why?
|
| Leukocytosis | 1 | 2022 | 13 | 0.050 |
Why?
|
| Microscopy, Electron | 1 | 2002 | 351 | 0.050 |
Why?
|
| Antigens, Neoplasm | 1 | 2003 | 132 | 0.050 |
Why?
|
| Rupture | 1 | 2022 | 29 | 0.050 |
Why?
|
| Transcriptional Activation | 2 | 2015 | 226 | 0.050 |
Why?
|
| ADAM Proteins | 1 | 2002 | 53 | 0.050 |
Why?
|
| Genes, Regulator | 1 | 2002 | 17 | 0.050 |
Why?
|
| Enterobacteriaceae | 1 | 2002 | 29 | 0.050 |
Why?
|
| Ubiquitins | 1 | 2022 | 22 | 0.050 |
Why?
|
| Microscopy, Confocal | 1 | 2003 | 337 | 0.050 |
Why?
|
| Mannose-Binding Lectins | 1 | 2002 | 8 | 0.050 |
Why?
|
| Luteinizing Hormone | 1 | 2002 | 31 | 0.050 |
Why?
|
| Embryo Implantation | 1 | 2002 | 17 | 0.050 |
Why?
|
| Glasgow Coma Scale | 1 | 2022 | 65 | 0.050 |
Why?
|
| Immunoglobulin Domains | 1 | 2021 | 2 | 0.050 |
Why?
|
| Telomere Shortening | 1 | 2021 | 8 | 0.050 |
Why?
|
| Epitope Mapping | 1 | 2021 | 10 | 0.050 |
Why?
|
| Reperfusion | 1 | 2022 | 78 | 0.050 |
Why?
|
| Immunoglobulin Fragments | 1 | 2021 | 14 | 0.050 |
Why?
|
| Case-Control Studies | 3 | 2010 | 1548 | 0.050 |
Why?
|
| Tight Junctions | 1 | 2021 | 25 | 0.050 |
Why?
|
| Rats | 2 | 2007 | 5300 | 0.050 |
Why?
|
| Immunoblotting | 2 | 2014 | 254 | 0.050 |
Why?
|
| Random Allocation | 2 | 2014 | 442 | 0.050 |
Why?
|
| DNA, Mitochondrial | 1 | 2022 | 84 | 0.050 |
Why?
|
| B7-1 Antigen | 1 | 2021 | 20 | 0.050 |
Why?
|
| Protein Structure, Secondary | 1 | 2021 | 136 | 0.050 |
Why?
|
| Binding Sites | 1 | 2003 | 631 | 0.050 |
Why?
|
| Combined Modality Therapy | 2 | 2020 | 951 | 0.050 |
Why?
|
| Time-to-Treatment | 1 | 2022 | 117 | 0.050 |
Why?
|
| Basic-Leucine Zipper Transcription Factors | 1 | 2021 | 19 | 0.050 |
Why?
|
| Triage | 1 | 2022 | 109 | 0.050 |
Why?
|
| Pyruvate Dehydrogenase Complex | 1 | 2020 | 9 | 0.050 |
Why?
|
| Pyruvic Acid | 1 | 2020 | 9 | 0.050 |
Why?
|
| PubMed | 3 | 2005 | 21 | 0.050 |
Why?
|
| Acetyl Coenzyme A | 1 | 2020 | 10 | 0.050 |
Why?
|
| Citric Acid Cycle | 1 | 2020 | 15 | 0.050 |
Why?
|
| Respiratory Function Tests | 2 | 2011 | 123 | 0.050 |
Why?
|
| Oxidative Phosphorylation | 1 | 2020 | 54 | 0.050 |
Why?
|
| NF-kappa B | 2 | 2015 | 432 | 0.050 |
Why?
|
| Pregnancy | 1 | 2006 | 2331 | 0.050 |
Why?
|
| Molecular Targeted Therapy | 1 | 2021 | 170 | 0.050 |
Why?
|
| Hepatitis A Virus Cellular Receptor 2 | 1 | 2020 | 2 | 0.050 |
Why?
|
| Receptors, Estrogen | 1 | 2021 | 142 | 0.050 |
Why?
|
| Intestinal Mucosa | 1 | 2021 | 219 | 0.050 |
Why?
|
| Nuclear Receptor Subfamily 4, Group A, Member 1 | 1 | 2020 | 5 | 0.050 |
Why?
|
| Injections, Intralesional | 1 | 2020 | 25 | 0.050 |
Why?
|
| Glycolysis | 1 | 2020 | 79 | 0.050 |
Why?
|
| Single Photon Emission Computed Tomography Computed Tomography | 1 | 2020 | 9 | 0.050 |
Why?
|
| Receptor, ErbB-2 | 1 | 2021 | 128 | 0.050 |
Why?
|
| Genetic Markers | 2 | 2011 | 144 | 0.050 |
Why?
|
| Disease-Free Survival | 1 | 2021 | 349 | 0.050 |
Why?
|
| Oncolytic Viruses | 1 | 2020 | 17 | 0.050 |
Why?
|
| Cluster Analysis | 2 | 2013 | 218 | 0.050 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2020 | 38 | 0.050 |
Why?
|
| Research Design | 1 | 2004 | 729 | 0.050 |
Why?
|
| Lactic Acid | 1 | 2020 | 86 | 0.050 |
Why?
|
| Matrix Metalloproteinase 2 | 3 | 2005 | 145 | 0.050 |
Why?
|
| Protein Binding | 1 | 2003 | 1027 | 0.050 |
Why?
|
| Thrombolytic Therapy | 1 | 2022 | 233 | 0.050 |
Why?
|
| Injections, Intravenous | 1 | 2020 | 215 | 0.050 |
Why?
|
| Immunoglobulin G | 3 | 2007 | 481 | 0.040 |
Why?
|
| Haemophilus influenzae | 1 | 2019 | 16 | 0.040 |
Why?
|
| Clodronic Acid | 1 | 2019 | 9 | 0.040 |
Why?
|
| Nitrophenols | 1 | 2019 | 14 | 0.040 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2019 | 61 | 0.040 |
Why?
|
| Streptococcus pneumoniae | 1 | 2019 | 32 | 0.040 |
Why?
|
| Neurologic Examination | 1 | 2019 | 107 | 0.040 |
Why?
|
| Secretory Leukocyte Peptidase Inhibitor | 1 | 2018 | 1 | 0.040 |
Why?
|
| Caspases | 1 | 2019 | 194 | 0.040 |
Why?
|
| Chemotaxis | 2 | 2011 | 38 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 3 | 2005 | 369 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2020 | 211 | 0.040 |
Why?
|
| Epigenesis, Genetic | 2 | 2011 | 163 | 0.040 |
Why?
|
| Biphenyl Compounds | 1 | 2019 | 184 | 0.040 |
Why?
|
| Fibrinolytic Agents | 1 | 2022 | 377 | 0.040 |
Why?
|
| Protease Inhibitors | 1 | 2018 | 76 | 0.040 |
Why?
|
| Matrix Metalloproteinase 3 | 2 | 2011 | 22 | 0.040 |
Why?
|
| Sulfonamides | 1 | 2019 | 141 | 0.040 |
Why?
|
| Body Mass Index | 1 | 2022 | 866 | 0.040 |
Why?
|
| Proteolysis | 1 | 2018 | 97 | 0.040 |
Why?
|
| DNA Methylation | 1 | 2019 | 192 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2004 | 2004 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2018 | 260 | 0.040 |
Why?
|
| Bacteria | 1 | 2019 | 193 | 0.040 |
Why?
|
| Piperazines | 1 | 2019 | 206 | 0.040 |
Why?
|
| Registries | 1 | 2021 | 730 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2019 | 332 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2019 | 652 | 0.040 |
Why?
|
| Nitric Oxide | 1 | 2019 | 382 | 0.040 |
Why?
|
| Systole | 1 | 2017 | 149 | 0.040 |
Why?
|
| Diastole | 1 | 2017 | 161 | 0.040 |
Why?
|
| Ovalbumin | 2 | 2007 | 33 | 0.040 |
Why?
|
| Recurrence | 1 | 2019 | 948 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 648 | 0.040 |
Why?
|
| Protease Nexins | 2 | 2006 | 8 | 0.040 |
Why?
|
| Serpin E2 | 2 | 2006 | 8 | 0.040 |
Why?
|
| Crosses, Genetic | 2 | 2006 | 60 | 0.030 |
Why?
|
| Nebulizers and Vaporizers | 2 | 2006 | 34 | 0.030 |
Why?
|
| Cyclin D1 | 1 | 2015 | 37 | 0.030 |
Why?
|
| Policy Making | 2 | 2005 | 51 | 0.030 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2015 | 201 | 0.030 |
Why?
|
| Interleukin-10 | 1 | 2015 | 144 | 0.030 |
Why?
|
| Obesity | 1 | 2022 | 1074 | 0.030 |
Why?
|
| ras Proteins | 1 | 2015 | 102 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2014 | 132 | 0.030 |
Why?
|
| Abdomen | 1 | 2014 | 80 | 0.030 |
Why?
|
| Aggrecans | 1 | 2013 | 13 | 0.030 |
Why?
|
| CD28 Antigens | 1 | 2013 | 12 | 0.030 |
Why?
|
| CD4 Antigens | 1 | 2013 | 42 | 0.030 |
Why?
|
| Prognosis | 2 | 2013 | 2093 | 0.030 |
Why?
|
| Transcription, Genetic | 2 | 2005 | 562 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 2017 | 718 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2019 | 711 | 0.030 |
Why?
|
| Intervertebral Disc | 1 | 2013 | 51 | 0.030 |
Why?
|
| Activating Transcription Factor 6 | 1 | 2012 | 6 | 0.030 |
Why?
|
| Eukaryotic Initiation Factor-2 | 1 | 2012 | 17 | 0.030 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2014 | 235 | 0.030 |
Why?
|
| Heat-Shock Proteins | 1 | 2012 | 69 | 0.030 |
Why?
|
| Pennsylvania | 1 | 2012 | 46 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2013 | 306 | 0.030 |
Why?
|
| Immunodominant Epitopes | 1 | 2011 | 13 | 0.030 |
Why?
|
| Weight Loss | 1 | 2014 | 319 | 0.030 |
Why?
|
| Antigens, CD | 2 | 2003 | 230 | 0.030 |
Why?
|
| Airway Remodeling | 1 | 2011 | 7 | 0.030 |
Why?
|
| Tomography, Spiral Computed | 1 | 2012 | 57 | 0.030 |
Why?
|
| Whole-Body Irradiation | 1 | 2011 | 52 | 0.030 |
Why?
|
| Cone-Beam Computed Tomography | 1 | 2012 | 52 | 0.030 |
Why?
|
| Carcinoma | 1 | 2013 | 215 | 0.030 |
Why?
|
| CX3C Chemokine Receptor 1 | 1 | 2011 | 2 | 0.020 |
Why?
|
| Wnt Proteins | 1 | 2011 | 57 | 0.020 |
Why?
|
| Adjuvants, Immunologic | 1 | 2011 | 63 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2012 | 567 | 0.020 |
Why?
|
| Observer Variation | 1 | 2012 | 330 | 0.020 |
Why?
|
| Receptors, Aryl Hydrocarbon | 1 | 2011 | 46 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2011 | 242 | 0.020 |
Why?
|
| Methacholine Chloride | 1 | 2010 | 20 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2017 | 1447 | 0.020 |
Why?
|
| Aging | 2 | 2010 | 911 | 0.020 |
Why?
|
| Neoplastic Stem Cells | 1 | 2011 | 84 | 0.020 |
Why?
|
| Th17 Cells | 1 | 2011 | 116 | 0.020 |
Why?
|
| Parathyroid Hormone-Related Protein | 1 | 2009 | 15 | 0.020 |
Why?
|
| Transplantation, Heterotopic | 1 | 2009 | 7 | 0.020 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2009 | 15 | 0.020 |
Why?
|
| Blood Cells | 1 | 2009 | 27 | 0.020 |
Why?
|
| Gels | 1 | 2009 | 55 | 0.020 |
Why?
|
| Young Adult | 1 | 2021 | 5708 | 0.020 |
Why?
|
| Skull | 1 | 2009 | 63 | 0.020 |
Why?
|
| Trachea | 1 | 2009 | 48 | 0.020 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2009 | 12 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2010 | 118 | 0.020 |
Why?
|
| RANK Ligand | 1 | 2009 | 73 | 0.020 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2009 | 35 | 0.020 |
Why?
|
| Family Health | 1 | 2009 | 83 | 0.020 |
Why?
|
| Caveolae | 1 | 2008 | 3 | 0.020 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2008 | 12 | 0.020 |
Why?
|
| Fetus | 1 | 2009 | 157 | 0.020 |
Why?
|
| Lung Compliance | 1 | 2008 | 10 | 0.020 |
Why?
|
| Models, Genetic | 1 | 2009 | 161 | 0.020 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2008 | 95 | 0.020 |
Why?
|
| Protein Phosphatase 2 | 1 | 2008 | 67 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2008 | 63 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2008 | 238 | 0.020 |
Why?
|
| Mesoderm | 1 | 2009 | 231 | 0.020 |
Why?
|
| Health Services Needs and Demand | 1 | 2009 | 149 | 0.020 |
Why?
|
| Cellular Senescence | 1 | 2008 | 112 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2009 | 235 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2008 | 492 | 0.020 |
Why?
|
| Lung Injury | 1 | 2007 | 38 | 0.020 |
Why?
|
| Glycocalyx | 1 | 2006 | 1 | 0.020 |
Why?
|
| Syk Kinase | 1 | 2006 | 10 | 0.020 |
Why?
|
| Logistic Models | 1 | 2010 | 1419 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2010 | 1465 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2010 | 1054 | 0.020 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2006 | 52 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2007 | 233 | 0.020 |
Why?
|
| Animals, Newborn | 1 | 2007 | 396 | 0.020 |
Why?
|
| Lod Score | 1 | 2005 | 14 | 0.020 |
Why?
|
| Drug Resistance | 1 | 2007 | 223 | 0.020 |
Why?
|
| Complement C3 | 1 | 2006 | 101 | 0.020 |
Why?
|
| Fucosyltransferases | 1 | 2005 | 6 | 0.020 |
Why?
|
| Software | 1 | 2008 | 418 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2008 | 880 | 0.020 |
Why?
|
| Mast Cells | 1 | 2006 | 113 | 0.020 |
Why?
|
| Tissue Extracts | 1 | 2005 | 10 | 0.020 |
Why?
|
| Myelin-Associated Glycoprotein | 1 | 2005 | 7 | 0.020 |
Why?
|
| Myelin Proteins | 1 | 2005 | 21 | 0.020 |
Why?
|
| Myelin-Oligodendrocyte Glycoprotein | 1 | 2005 | 17 | 0.020 |
Why?
|
| Smad2 Protein | 1 | 2005 | 42 | 0.020 |
Why?
|
| Cathepsin G | 1 | 2005 | 3 | 0.020 |
Why?
|
| Respiratory Burst | 1 | 2005 | 6 | 0.020 |
Why?
|
| NADPH Oxidase 2 | 1 | 2005 | 16 | 0.020 |
Why?
|
| Hydroxymethylglutaryl CoA Reductases | 1 | 2005 | 17 | 0.020 |
Why?
|
| Phagocytes | 1 | 2005 | 15 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 2005 | 94 | 0.020 |
Why?
|
| Computational Biology | 1 | 2007 | 190 | 0.020 |
Why?
|
| Child | 2 | 2009 | 6400 | 0.020 |
Why?
|
| Mice, Inbred A | 1 | 2005 | 4 | 0.020 |
Why?
|
| History, 20th Century | 1 | 2006 | 248 | 0.020 |
Why?
|
| Enzyme Precursors | 1 | 2005 | 27 | 0.020 |
Why?
|
| Ammonium Sulfate | 1 | 2005 | 6 | 0.020 |
Why?
|
| Calcium Chloride | 1 | 2005 | 38 | 0.020 |
Why?
|
| Ligands | 1 | 2006 | 317 | 0.020 |
Why?
|
| Blood Cell Count | 1 | 2005 | 35 | 0.020 |
Why?
|
| Solubility | 1 | 2005 | 134 | 0.020 |
Why?
|
| Glycosylation | 1 | 2005 | 185 | 0.020 |
Why?
|
| Hydroxamic Acids | 1 | 2005 | 84 | 0.020 |
Why?
|
| Antigens, Plant | 1 | 2004 | 3 | 0.020 |
Why?
|
| Matrix Metalloproteinases, Membrane-Associated | 1 | 2004 | 11 | 0.020 |
Why?
|
| Matrix Metalloproteinase 13 | 1 | 2004 | 24 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2009 | 848 | 0.020 |
Why?
|
| Point Mutation | 1 | 2005 | 97 | 0.020 |
Why?
|
| Endocytosis | 1 | 2005 | 113 | 0.020 |
Why?
|
| Hydrogen Peroxide | 1 | 2005 | 168 | 0.020 |
Why?
|
| Spleen | 1 | 2005 | 301 | 0.020 |
Why?
|
| Coculture Techniques | 1 | 2004 | 147 | 0.020 |
Why?
|
| Matrix Metalloproteinase 14 | 1 | 2004 | 44 | 0.020 |
Why?
|
| Dilatation | 1 | 2004 | 58 | 0.020 |
Why?
|
| Perfusion | 1 | 2004 | 131 | 0.020 |
Why?
|
| Autoimmunity | 1 | 2005 | 118 | 0.020 |
Why?
|
| Algorithms | 1 | 2010 | 1194 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2006 | 376 | 0.020 |
Why?
|
| Peritoneal Cavity | 1 | 2004 | 25 | 0.020 |
Why?
|
| Microscopy, Video | 1 | 2004 | 27 | 0.020 |
Why?
|
| Venules | 1 | 2004 | 8 | 0.020 |
Why?
|
| Scrotum | 1 | 2004 | 8 | 0.020 |
Why?
|
| Antigen-Antibody Complex | 1 | 2005 | 175 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2007 | 510 | 0.020 |
Why?
|
| Lipids | 1 | 2006 | 298 | 0.020 |
Why?
|
| Aorta, Abdominal | 1 | 2004 | 97 | 0.020 |
Why?
|
| Spinal Cord | 1 | 2005 | 244 | 0.020 |
Why?
|
| Bone Matrix | 1 | 2004 | 8 | 0.020 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 1 | 2005 | 133 | 0.020 |
Why?
|
| Chick Embryo | 1 | 2004 | 379 | 0.020 |
Why?
|
| Interleukin-1 | 1 | 2004 | 86 | 0.020 |
Why?
|
| Plasminogen Activators | 1 | 2003 | 19 | 0.010 |
Why?
|
| Nervous System Diseases | 1 | 2005 | 142 | 0.010 |
Why?
|
| Culture Media, Serum-Free | 1 | 2003 | 35 | 0.010 |
Why?
|
| Plasminogen | 1 | 2003 | 28 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 2004 | 165 | 0.010 |
Why?
|
| Culture Media, Conditioned | 1 | 2003 | 78 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2004 | 251 | 0.010 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2003 | 30 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2005 | 507 | 0.010 |
Why?
|
| CD40 Ligand | 1 | 2003 | 14 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2004 | 357 | 0.010 |
Why?
|
| Oxygen | 1 | 2005 | 386 | 0.010 |
Why?
|
| Cerebrovascular Circulation | 1 | 2005 | 296 | 0.010 |
Why?
|
| Epithelium, Corneal | 1 | 2003 | 3 | 0.010 |
Why?
|
| Lasers, Excimer | 1 | 2003 | 10 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2003 | 30 | 0.010 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2003 | 29 | 0.010 |
Why?
|
| Rabbits | 1 | 2004 | 509 | 0.010 |
Why?
|
| Endothelial Growth Factors | 1 | 2003 | 25 | 0.010 |
Why?
|
| Corneal Stroma | 1 | 2003 | 20 | 0.010 |
Why?
|
| Carotid Arteries | 1 | 2003 | 110 | 0.010 |
Why?
|
| Lymphokines | 1 | 2003 | 49 | 0.010 |
Why?
|
| Medulloblastoma | 1 | 2003 | 24 | 0.010 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2003 | 48 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 2002 | 76 | 0.010 |
Why?
|
| Yersinia enterocolitica | 1 | 2002 | 1 | 0.010 |
Why?
|
| Shigella flexneri | 1 | 2002 | 8 | 0.010 |
Why?
|
| Salmonella typhimurium | 1 | 2002 | 15 | 0.010 |
Why?
|
| Leukemia | 1 | 2003 | 117 | 0.010 |
Why?
|
| Virulence | 1 | 2002 | 51 | 0.010 |
Why?
|
| Quality of Life | 1 | 2010 | 1515 | 0.010 |
Why?
|
| Half-Life | 1 | 2002 | 96 | 0.010 |
Why?
|
| Cadherins | 1 | 2002 | 93 | 0.010 |
Why?
|
| Heterozygote | 1 | 2002 | 174 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2007 | 2453 | 0.010 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2003 | 317 | 0.010 |
Why?
|
| Acute Disease | 1 | 2003 | 658 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2002 | 852 | 0.010 |
Why?
|
| Muscle, Skeletal | 1 | 2004 | 396 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2003 | 659 | 0.010 |
Why?
|
| Sex Factors | 1 | 2003 | 1265 | 0.010 |
Why?
|
| Survival Rate | 1 | 2002 | 1055 | 0.010 |
Why?
|
| Myocardium | 1 | 2002 | 1204 | 0.010 |
Why?
|